| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0006-8993(01)03403-5 |
| P698 | PubMed publication ID | 11864629 |
| P50 | author | José J. Lucas | Q42463527 |
| P2093 | author name string | Yamamoto A | |
| Berrendero F | |||
| Ramos JA | |||
| Fernández-Ruiz JJ | |||
| Lastres-Becker I | |||
| Martín-Aparicio E | |||
| P2860 | cites work | Cannabinoids inhibit excitatory neurotransmission in the substantia nigra pars reticulata | Q28377147 |
| Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease | Q28588314 | ||
| Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice | Q29615357 | ||
| Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study | Q29615905 | ||
| Differential loss of striatal projection neurons in Huntington disease | Q33637273 | ||
| Recent advances in understanding the pathogenesis of Huntington's disease | Q33650539 | ||
| Brain cannabinoid systems as targets for the therapy of neurological disorders | Q34492167 | ||
| Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. | Q34602111 | ||
| Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system | Q34745063 | ||
| Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain | Q37413174 | ||
| Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry | Q38331458 | ||
| The activation of cannabinoid receptors in striatonigral GABAergic neurons inhibited GABA uptake. | Q42450193 | ||
| Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen | Q42487505 | ||
| Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice | Q42490465 | ||
| Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease. | Q43792416 | ||
| Effects of systemic 3-nitropropionic acid-induced lesions of the dorsal striatum on cannabinoid and mu-opioid receptor binding in the basal ganglia. | Q44330257 | ||
| Differences in G-protein activation by mu- and delta-opioid, and cannabinoid, receptors in rat striatum | Q44343153 | ||
| Selective vulnerability in Huntington's disease: preferential loss of cannabinoid receptors in lateral globus pallidus. | Q45289172 | ||
| Loss of cannabinoid receptors in the substantia nigra in Huntington's disease. | Q45290294 | ||
| Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease | Q45291252 | ||
| Advances in Huntington's disease: implications for experimental therapeutics | Q45296397 | ||
| The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease | Q45300428 | ||
| Ipsilateral turning behavior induced by unilateral microinjections of a cannabinoid into the rat subthalamic nucleus | Q47963301 | ||
| Neuron-specific enolase (NSE) and non-neuronal enolase (NNE) mRNAs are co-expressed in neurons of the rat cerebellum: in situ hybridization histochemistry | Q48255621 | ||
| Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent | Q48332786 | ||
| Tissue-specific generation of two preprotachykinin mRNAs from one gene by alternative RNA splicing | Q48384593 | ||
| 3-Nitropropionic acid's lethal triplet: cooperative pathways of neurodegeneration. | Q48403701 | ||
| Role of the subthalamic nucleus in cannabinoid actions in the substantia nigra of the rat. | Q48786464 | ||
| Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus. | Q48962147 | ||
| Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. | Q52060269 | ||
| Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function. | Q54001516 | ||
| Chronic CP-55,940 alters cannabinoid receptor mRNA in the rat brain: an in situ hybridization study | Q72110282 | ||
| delta 9-Tetrahydrocannabinol and anandamide enhance the ability of muscimol to induce catalepsy in the globus pallidus of rats | Q72270865 | ||
| The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behavior: role of nigrostriatal dopaminergic neurons | Q72302141 | ||
| Activational role of cannabinoids on movement | Q73575705 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Huntington's disease | Q190564 |
| cannabinoid receptor | Q421237 | ||
| cannabinoids | Q422936 | ||
| CNR2 | Q17907844 | ||
| P1104 | number of pages | 7 | |
| P304 | page(s) | 236-242 | |
| P577 | publication date | 2002-03-01 | |
| P1433 | published in | Brain Research | Q4955782 |
| P1476 | title | Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease | |
| P478 | volume | 929 |
| Q27324171 | A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice |
| Q35166600 | Biosynthesis of endocannabinoids and their modes of action in neurodegenerative diseases |
| Q33664105 | Brain CB₂ Receptors: Implications for Neuropsychiatric Disorders |
| Q38324480 | Cannabinoid Signaling and Neuroinflammatory Diseases: A Melting pot for the Regulation of Brain Immune Responses. |
| Q36067324 | Cannabinoid modulation of neuroinflammatory disorders. |
| Q37842745 | Cannabinoid receptor signalling in neurodegenerative diseases: a potential role for membrane fluidity disturbance |
| Q36155898 | Cannabinoids and Dementia: A Review of Clinical and Preclinical Data |
| Q36977766 | Cannabinoids and neuroprotection in basal ganglia disorders. |
| Q91934280 | Cannabinoids and the expanded endocannabinoid system in neurological disorders |
| Q40701861 | Cannabinoids for the Treatment of Movement Disorders. |
| Q38563981 | Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications |
| Q34549222 | Cannabis and cannabinoid receptors: from pathophysiology to therapeutic options |
| Q44687714 | Delayed onset of Huntington's disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors |
| Q38593124 | Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others |
| Q36003798 | Gene-environment interplay in neurogenesis and neurodegeneration |
| Q44346477 | Huntingtin distribution among striatal output neurons of normal rat brain. |
| Q47242856 | Immunolocalization of CB1 receptor in rat striatal neurons: a confocal microscopy study. |
| Q73304376 | Loss of cannabinoid CB(1) receptors in the basal ganglia in the late akinetic phase of rats with experimental Huntington's disease |
| Q42478056 | Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. |
| Q64269587 | Major Contribution of Somatostatin-Expressing Interneurons and Cannabinoid Receptors to Increased GABA Synaptic Activity in the Striatum of Huntington’s Disease Mice |
| Q29248766 | Molecular Imaging Markers to Track Huntington’s Disease Pathology |
| Q26853025 | Mouse models of polyglutamine diseases: review and data table. Part I |
| Q42512972 | Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage |
| Q90439419 | Overview of Huntington's Disease Models: Neuropathological, Molecular, and Behavioral Differences |
| Q37872326 | Prospects for cannabinoid therapies in basal ganglia disorders |
| Q39409413 | Regulation of opioid and cannabinoid receptor genes in human neuroblastoma and T cells by the epigenetic modifiers trichostatin A and 5-aza-2'-deoxycytidine. |
| Q36931043 | Selective expression of mutant huntingtin during development recapitulates characteristic features of Huntington's disease |
| Q36684263 | The corticostriatal pathway in Huntington's disease |
| Q37394164 | The endocannabinoid system as a target for the treatment of motor dysfunction |
| Q34098196 | The endocannabinoid system as a target for the treatment of neurodegenerative disease |
| Q24648473 | The endocannabinoid system as an emerging target of pharmacotherapy |
| Q34786832 | The endogenous cannabinoid system and the basal ganglia. biochemical, pharmacological, and therapeutic aspects. |
| Q35171113 | The therapeutic potential of cannabinoids for movement disorders |
| Q36341688 | The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids |
| Q37402927 | The therapeutic potential of novel cannabinoid receptors |
| Q34974856 | The therapeutic potential of the cannabinoids in neuroprotection |
| Q36752799 | Transcriptional signatures in Huntington's disease |
| Q42948746 | Type 1 cannabinoid receptor mapping with [18F]MK-9470 PET in the rat brain after quinolinic acid lesion: a comparison to dopamine receptors and glucose metabolism |
Search more.